What it is
Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), molecular formula C₁₄H₂₂N₄O₉, molecular weight 390.35 Da, CAS 307297-39-8, PubChem CID 219042. It was synthesized at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues in the early 1990s as the putative active tetrapeptide within Epithalamin, a bovine pineal polypeptide complex used in the Russian geriatric-medicine tradition. Epitalon was identified as the shared minimal bioactive sequence between pineal gland and retinal peptide preparations — a finding the Khavinson group attributes to the common embryonal origin of the two tissues — and was later reported (2017) to be detectable in physiological human pineal extracts, reclassifying it as an endogenous peptide rather than a purely synthetic analogue. Epitalon is not a currently approved finished drug product in any major jurisdiction and is sold in the United States solely as a research chemical.
In plain English
Epitalon is a lab-made peptide — a chain of just four amino acids (the building blocks of proteins): alanine, glutamic acid, aspartic acid, and glycine, abbreviated AEDG. Vladimir Khavinson's team in St. Petersburg made it in the early 1990s. They built it to be the active piece of an older cow-pineal-gland extract called Epithalamin that was used in Soviet-era aging medicine. The Khavinson group later reported (in 2017) that trace amounts of this same four-peptide chain also appear naturally in the human pineal gland, so they reclassified it as something the body already makes rather than a purely synthetic drug. It's not an approved drug anywhere in the world, and in the U.S. it's only sold as a research chemical for lab studies.
How it works
- 01
hTERT promoter activation and telomerase reactivation (cell culture)
Khavinson, Bondarev & Butyugov (2003, Bull Exp Biol Med) reported that addition of Epitalon to cultures of telomerase-negative human fetal fibroblasts induced expression of the hTERT catalytic subunit, reconstituted telomerase enzymatic activity, and produced measurable telomere elongation. The proposed mechanism is direct interaction with ATTTC-like motifs in the hTERT promoter — a sequence-specific DNA-binding hypothesis advanced by the Khavinson group based on computational docking and correlation between motif occurrence and bioactivity. This proposed DNA-binding mechanism has not been confirmed by an independent Western lab using radioligand binding, EMSA, or ChIP-seq.
In plain English
It seems to turn on the telomere-rebuilding enzyme (in lab dishes)
In a 2003 Russian study, adding Epitalon to human cells in a dish seemed to turn on telomerase — the enzyme that rebuilds the protective caps (telomeres) on the ends of your chromosomes. Those caps normally shrink as cells divide, and when they get too short, the cell stops dividing. The Russian group's theory: Epitalon directly sticks to a specific DNA sequence near the telomerase gene and helps switch it on. That theory is based on computer modeling. No outside lab has confirmed it with the standard molecular-biology tools that could prove or disprove it.
- 02
Bypassing the Hayflick limit and replicative-senescence extension
In the same 2003 fibroblast program, Epitalon-treated cells divided beyond 44 passages compared with 34 passages in untreated controls — a reported extension of replicative capacity consistent with telomerase reactivation. No independent lab has reproduced this specific fibroblast Hayflick-limit extension in peer-reviewed Western literature, and the finding remains the single most-cited but least-replicated mechanistic claim associated with Epitalon.
In plain English
Cells divided more times than they normally can (lab dish only)
Normal human cells can only divide about 34 times before they stop — that's called the Hayflick limit. In the 2003 Russian study, Epitalon-treated cells divided 44 times, ten more. This is the single most-quoted Epitalon result online. It's also the single least-repeated: no Western lab has ever published the same finding.
- 03
Dual-pathway telomere maintenance: telomerase-dependent in normal cells, ALT in cancer cells
Bagherpour Doun et al. (2025, Biogerontology) treated breast-cancer lines 21NT and BT474 and normal epithelial/fibroblast cells with 0.5 and 1 µg/mL Epitalon for 4 days. hTERT expression was reported as upregulated 12-fold in 21NT at 1 µg/mL and 5-fold in BT474 at 0.5 µg/mL, with qPCR and immunofluorescence used to demonstrate dose-dependent telomere extension. The authors describe two distinct pathways: telomerase-dependent lengthening in normal cells (requiring approximately 3 weeks of incubation) and Alternative Lengthening of Telomeres (ALT) activation in cancer cells within 4 days. The ALT-in-cancer finding is biologically important — it directly raises the question of whether Epitalon could accelerate telomere maintenance in pre-malignant or malignant populations in vivo. No controlled human study has addressed this oncologic safety question.
In plain English
It lengthens telomeres two different ways — and one of them is worrying
A 2025 study tested Epitalon on two breast-cancer cell lines and on normal cells. Normal cells lengthened their telomeres slowly through the usual enzyme route (about 3 weeks). Cancer cells lengthened theirs FAST — within 4 days — through a backup route called ALT. That's an important warning sign. If Epitalon can jump-start the cancer-style route in a dish, it may do the same to pre-cancer cells in a person. No controlled human study has looked at this cancer-safety question.
- 04
Heterochromatin decondensation and epigenetic modulation (aged lymphocytes)
Khavinson-group cytogenetic work (reviewed in Khavinson 2020, Int J Mol Sci) reported that Epitalon induced decondensation of pericentromeric heterochromatin in cultured lymphocytes from donors aged 76–80, interpreted as partial restoration of a 'younger' chromatin accessibility pattern. The study framework relies on morphological chromatin scoring rather than ATAC-seq or single-cell epigenomic readouts, and has not been replicated with modern chromatin-accessibility methods.
In plain English
It seems to "loosen" aged DNA packaging (lab dish only)
Your DNA is packaged tightly — and it gets tighter with age, which can silence useful genes. Russian studies reported that Epitalon "loosened" this packaging in immune cells taken from people in their late 70s, making the chromatin look more like that of a younger person. They measured it by eye under a microscope, not with the modern sequencing tools that everyone else uses today. It has not been re-checked with current methods.
- 05
Pineal-gland melatonin biosynthesis (AANAT / pCREB)
Khavinson et al. (2012, Bull Exp Biol Med) showed in rat pinealocyte culture that Epitalon increased AANAT (arylalkylamine-N-acetyltransferase) and pCREB protein levels and raised melatonin output in the medium, with norepinephrine co-administration producing synergistic induction. Non-human-primate work from the same group reported restoration of nocturnal melatonin peaks in aged monkeys. This is the mechanistic basis for the 'circadian-rhythm normalization' outcome. Human-subject data with formal salivary or plasma melatonin measurement under placebo control is absent.
In plain English
It boosts melatonin production in pineal-gland cells
Your pineal gland makes melatonin, the sleep hormone. In rat pineal-gland cells in a dish, Epitalon raised the levels of two proteins involved in melatonin production and increased melatonin output. In older monkeys, the same Russian group reported that Epitalon restored the normal nighttime melatonin spike. That's the reason some people call Epitalon a "circadian-rhythm" drug. No controlled human trial has actually measured melatonin with and without Epitalon.
- 06
Mitochondrial preservation and ROS attenuation
Gao et al. (2022, Aging) reported that 0.1 mM Epitalon in vitro reduced intracellular ROS, preserved spindle morphology, increased mitochondrial membrane potential (ΔΨm via JC-1), and increased mtDNA copy number during post-ovulatory aging of mouse oocytes. Bovine-oocyte work (Life Sciences 2025) extended this to cumulus-cell and blastocyst outcomes. These effects may reflect the 'non-canonical' cytoprotective functions of TERT (mitochondrial-membrane TERT is an established topic independent of Epitalon), but the causal chain from peptide to mitochondrial phenotype has not been fully dissected.
In plain English
It protected cell "power plants" in aging egg cells
Egg cells that wait too long to be fertilized get damaged — their mitochondria (the cell's power plants) stop working well, and they build up stress molecules. In a 2022 lab-dish study, Epitalon protected aging mouse egg cells from that damage. A 2025 study repeated it in cow eggs and frozen embryos. This might be because telomerase has a separate job inside mitochondria, independent of telomeres — but the step-by-step connection from Epitalon to healthier mitochondria hasn't been fully worked out.
- 07
What is NOT known about the mechanism
No receptor or specific molecular binding partner for Epitalon has been identified outside the proposed DNA-promoter interaction model, and that model has not been validated by an independent structural study. Human pharmacokinetics — Cmax, Tmax, half-life, tissue distribution, CNS penetration, oral vs subcutaneous vs intranasal bioavailability — have not been published in peer-reviewed Western literature. The proposed 'epigenetic modulator' framing depends on Khavinson-group chromatin morphology methods rather than modern sequencing-based readouts. The oncologic implications of any telomerase or ALT activator in humans have not been studied under controlled conditions. Receptor pharmacology, human PK, and independent-lab mechanistic replication are the three missing pillars that prevent any outcome on this page from clearing the C/D boundary.
In plain English
What we still don't know about how it works
No one has found the specific protein receiver that Epitalon attaches to. The only proposed mechanism — Epitalon sticking directly to DNA near the telomerase gene — has not been confirmed by an outside lab using standard molecular-biology tools. There are no published studies showing how the human body absorbs, uses, and clears Epitalon, or the best way to give it (injection vs nose spray vs by mouth). The cancer-safety question — what telomerase activation does in people over time — has not been studied in a controlled human trial. These three gaps (receptor, human handling, outside-lab replication) are the main reasons no claim on this page grades higher than D.